MARKET

BIO

BIO

Bio Rad
NYSE

Real-time Quotes | Nasdaq Last Sale

601.68
-1.29
-0.21%
After Hours: 601.68 0 0.00% 16:19 06/11 EDT
OPEN
605.92
PREV CLOSE
602.97
HIGH
605.92
LOW
598.30
VOLUME
95.71K
TURNOVER
--
52 WEEK HIGH
689.00
52 WEEK LOW
425.43
MARKET CAP
17.91B
P/E (TTM)
4.426
1D
5D
1M
3M
1Y
5Y
Bio-Rad Laboratories Stock Gives Every Indication Of Being Significantly Overvalued
GuruFocus News · 5d ago
Research Alert: CFRA Lowers Opinion On Shares Of Bio-rad Laboratories To Buy From Strong Buy
MT Newswires · 6d ago
Fed Circ affirms mixed ITC ruling in 10x and Bio-Rad's patent fight
The U.S. Court of Appeals for the Federal Circuit affirmed an International Trade Commission ruling Friday that some genetic-analysis products imported by 10x Genomics Inc infringe rival Bio-Rad Laboratories Inc's patents.
Reuters · 05/28 22:29
Bio-Rad to Participate at Jefferies Virtual Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive V...
Business Wire · 05/20 12:30
Miura Global Management, LLC Buys First Citizens BancShares Inc, TripAdvisor Inc, The Walt ...
GuruFocus News · 05/17 19:38
Mirabella Financial Services Llp Buys T-Mobile US Inc, VanEck Vectors Semiconductor ETF, CVS ...
GuruFocus News · 05/17 17:38
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be...
Benzinga · 05/13 17:41
Was The Smart Money Right About Bio-Rad Laboratories, Inc. (BIO)?
Insider Monkey · 05/10 22:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIO. Analyze the recent business situations of Bio Rad through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIO stock price target is 755.00 with a high estimate of 775.00 and a low estimate of 735.00.
EPS
Institutional Holdings
Institutions: 641
Institutional Holdings: 21.03M
% Owned: 70.64%
Shares Outstanding: 29.76M
TypeInstitutionsShares
Increased
198
1.50M
New
62
169.85K
Decreased
143
1.20M
Sold Out
58
483.53K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.06%
Key Executives
Chairman/President/Chief Executive Officer/Director
Norman Schwartz
Chief Financial Officer/Executive Vice President
Ilan Daskal
Chief Operating Officer/Executive Vice President
Andrew Last
Executive Vice President/General Counsel/Secretary
Timothy Ernst
Executive Vice President
Michael Crowley
Executive Vice President
Giovanni Magni
Executive Vice President
Annette Tumolo
Executive Vice President
Dara Wright
Vice President/Treasurer
Ronald Hutton
Senior Vice President/Chief Accounting Officer
Ajit Ramalingam
Lead Director/Independent Director
Gregory Hinckley
Director
Alice Schwartz
Independent Director
Jeffrey Edwards
Independent Director
Melinda Litherland
Independent Director
Arnold Pinkston
No Data
  • All
  • Financials
  • Insiders
More
About BIO
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Webull offers kinds of Bio-Rad Laboratories, Inc. stock information, including NYSE:BIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIO stock methods without spending real money on the virtual paper trading platform.